Excent Capital Launches World Cup 2026 Incentive Program for Global Partners

Mexico City, Mexico – January 10, 2026 – (SeaPRwire) – Excent Capital has announced the launch of a new incentive program for its global partner network, offering exclusive experiences connected to the 2026 World Cu as part of its ongoing commitment to long-term collaboration and partner engagement. The initiative is designed to recognise partner performance and strengthen relationships through experiences that go beyond traditional rewards. Depending on performance tiers, partners may qualify for packages that include match tickets, travel arrangements, accommodation, and curated experiences in the United States during the tournament. Rather than focusing solely on volume, the program is structured to encourage sustainable growth, strategic alignment, and continued collaboration between Excent Capital and its partners. The incentive tiers are linked to clearly defined performance benchmarks, ensuring transparency and consistency across regions. “We work very closely with our partners on a daily basis, and this initiative is a way to give something back that goes beyond numbers,” said Andrés Espinosa, Senior Business Development Manager at Excent Capital. The World Cup 2026 incentive program is open to eligible partners worldwide and will run until May 15. Participation details, performance criteria, and tier qualifications are communicated directly to partners through Excent Capital’s regional business development teams. About Excent Capital Excent Capital is a global trading broker offering access to a wide range of financial markets. Operating on proprietary, in-house developed technology, the company focuses on transparency, execution quality, and partner-driven growth, supporting partners through education, consistent market insight, and collaborative initiatives. Contact Information Organization: Excent Capital Contact Person: Ryccielli Ongaratto, Marketing Manager Email: support@excent.capital Website: https://excent.capital/

普瑞美赛尔公司亮相摩根大通2026年医疗健康大会

佛罗里达州迈阿密市, 2026年1月10日 - (亚太商讯 via SeaPRwire.com) - 临床阶段细胞免疫疗法公司普瑞赛尔(PromiCell, Inc.,以下简称“公司”)今日宣布,其首席医学官John Lee医学博士、哲学博士将出席摩根大通2026年医疗健康大会,并就公司核心资产PRO CAR-1的阶段性研究结果进行专题报告。该产品为STEAP1靶向CAR-T细胞疗法,目前正处于治疗转移性去势抵抗性前列腺癌(mCRPC)的首个人体I期临床试验阶段。-201A(一种针对STEAP1的CAR-T细胞疗法)的中期研究结果。该疗法目前正处于治疗转移性去势抵抗性前列腺癌(mCRPC)的首个人体I期临床试验阶段。演讲将于2025年1月12日(星期一)太平洋标准时间上午11:15在加利福尼亚州旧金山举行的2026生物技术展示会上进行,地点为Franciscan D 宴会厅层)举行。关于普瑞美赛尔公司PromiCell是一家临床阶段细胞免疫疗法公司,其候选产品代表高度差异化且创新的CAR-T与TCR-T平台,将分别针对实体瘤与血液肿瘤类型进行开发。我们的创新产品管线包括STEAP1 CAR-T细胞、HA-1 TCR-T细胞及CD33 CAR-T细胞,适用于治疗mCRPC、尤文氏肉瘤、复发性白血病及急性髓系白血病患者。我们新一代嵌合抗原受体CAR-T细胞疗法旨在突破肿瘤逃逸、疾病复发及免疫规避的关键机制。公司科学家作为CAR-T疗法领域的先驱者,正携手践行战胜癌症、为患者创造更多治愈机会的使命。了解更多信息请访问 www.promicell.com 。 联系方式:305-433-1287anthony@promicell.com 来源:普罗米赛尔 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com